{"id":25,"date":"2026-10-28T11:43:02","date_gmt":"2026-10-28T11:43:02","guid":{"rendered":"https:\/\/biocytara.com\/?page_id=25"},"modified":"2026-11-01T14:38:06","modified_gmt":"2026-11-01T14:38:06","slug":"products","status":"publish","type":"page","link":"https:\/\/biocytara.com\/?page_id=25","title":{"rendered":"PRODUCTS"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"25\" class=\"elementor elementor-25\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-66729e4d e-flex e-con-boxed e-con e-parent\" data-id=\"66729e4d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-653c8cb4 e-con e-atomic-element e-flexbox-base e-default-div e-653c8cb4-d75d656 \" data-id=\"653c8cb4\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"653c8cb4\" data-e-type=\"e-flexbox\" data-id=\"653c8cb4\">\n    \t\t<div class=\"elementor-element elementor-element-3939091d elementor-widget elementor-widget-spacer\" data-id=\"3939091d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-41aad862 elementor-widget elementor-widget-text-editor\" data-id=\"41aad862\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h1>Aspacytarabine (BST-236)<\/h1>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1e4d8e84 e-flex e-con-boxed e-con e-parent\" data-id=\"1e4d8e84\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-8e6dcc3 e-con e-atomic-element e-flexbox-base e-default-div e-19f666e \" data-id=\"8e6dcc3\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"8e6dcc3\" data-e-type=\"e-flexbox\" data-id=\"8e6dcc3\">\n    <div class=\"elementor-element elementor-element-e6d70db e-con e-atomic-element e-flexbox-base e-default-div e-aff991d \" data-id=\"e6d70db\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"e6d70db\" data-e-type=\"e-flexbox\" data-id=\"e6d70db\">\n    \t\t<div class=\"elementor-element elementor-element-2013ae69 elementor-widget elementor-widget-spacer\" data-id=\"2013ae69\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"31d408c2\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"31d408c2\"><strong>Innovation Built on Established Science<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-40de4d2d elementor-widget elementor-widget-text-editor\" data-id=\"40de4d2d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>BioCytara&#8217;s lead development asset is <strong>Aspacytarabine <\/strong>(BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine.<\/p><p>Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n<div class=\"elementor-element elementor-element-6d6269f e-con e-atomic-element e-flexbox-base e-default-div e-b65e4d3 \" data-id=\"6d6269f\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"6d6269f\" data-e-type=\"e-flexbox\" data-id=\"6d6269f\">\n    \t\t<div class=\"elementor-element elementor-element-a325379 elementor-widget elementor-widget-image\" data-id=\"a325379\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"600\" src=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/AspacytarabineMI-V2-1024x768.png\" class=\"attachment-large size-large wp-image-161\" alt=\"\" srcset=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/AspacytarabineMI-V2-1024x768.png 1024w, https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/AspacytarabineMI-V2-300x225.png 300w, https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/AspacytarabineMI-V2-768x576.png 768w, https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/AspacytarabineMI-V2.png 1448w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\n<\/div>\n<div class=\"elementor-element elementor-element-7dcdceee e-con e-atomic-element e-flexbox-base e-default-div e-7dcdceee-27802e9 \" data-id=\"7dcdceee\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"7dcdceee\" data-e-type=\"e-flexbox\" data-id=\"7dcdceee\">\n    \t\t\t<h2 data-interaction-id=\"2f7c48c5\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"2f7c48c5\"><strong>A Differentiated Cytarabine Prodrug<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-e597723 elementor-widget elementor-widget-text-editor\" data-id=\"e597723\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Aspacytarabine is an investigational antimetabolite composed of cytarabine chemically linked to the amino acid asparagine.<\/p><p>Cytarabine is a well-established chemotherapy agent used in the treatment of AML and other hematological malignancies.<\/p><p>Although cytarabine is highly active against leukemia cells, intensive treatment may be associated with significant toxicity, including neurological and gastrointestinal adverse effects.<\/p><p>Aspacytarabine was specifically designed to address some of these limitations.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a5367b8 elementor-widget elementor-widget-spacer\" data-id=\"a5367b8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"4a3dd8b\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"4a3dd8b\"><strong>How Aspacytarabine Works?<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-c00d99e elementor-widget elementor-widget-text-editor\" data-id=\"c00d99e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Aspacytarabine is administered intravenously as a prodrug that releases the active anticancer agent cytarabine following administration.<\/p><p>The intact prodrug is designed to be relatively inactive until converted to cytarabine.<\/p><p>This approach is intended to modify the pharmacokinetic profile of cytarabine, limiting high systemic peak concentrations that may contribute to treatment-related toxicity.<\/p><p>Preclinical and clinical research suggests that Aspacytarabine enable the administration of substantial cytarabine doses to patient populations who are unsuitable for conventional intensive cancer therapy.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-43c96e4 elementor-widget elementor-widget-image\" data-id=\"43c96e4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1774\" height=\"887\" src=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/MechanismV1.png\" class=\"attachment-full size-full wp-image-162\" alt=\"\" srcset=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/MechanismV1.png 1774w, https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/MechanismV1-300x150.png 300w, https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/MechanismV1-1024x512.png 1024w, https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/MechanismV1-768x384.png 768w, https:\/\/biocytara.com\/wp-content\/uploads\/2026\/11\/MechanismV1-1536x768.png 1536w\" sizes=\"(max-width: 1774px) 100vw, 1774px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-16da8e5 elementor-widget elementor-widget-spacer\" data-id=\"16da8e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"401e85d\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"401e85d\"><strong>Development Pipeline<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-8aae057 elementor-widget elementor-widget-text-editor\" data-id=\"8aae057\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><strong>Primary Indication:<\/strong> Acute Myeloid Leukemia (AML).<\/p><p><strong>Additional Opportunities:<\/strong><\/p><ul><li>Higher-risk Myelodysplastic Syndromes (MDS).<\/li><li>Relapsed or refractory AML.<\/li><li>Combination therapies.<\/li><li>Future oral formulation development.<\/li><\/ul><p><strong>Current Development Status<\/strong><\/p><p>Aspacytarabine has completed Phase 2b clinical evaluation as monotherapy in newly diagnosed AML patients considered unfit for intensive chemotherapy.<\/p><p>Additional studies have investigated its use in other R\/R AML and MDS populations and in combination regimens.<\/p><p>Further clinical development and regulatory approvals are required before commercial use.<\/p><p><strong>Aspacytarabine is an investigational product and is not yet approved for commercial treatment.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1ded052 elementor-widget elementor-widget-spacer\" data-id=\"1ded052\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"280d4d5\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"280d4d5\"><strong>Clinical Evidence<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-ef966de elementor-widget elementor-widget-text-editor\" data-id=\"ef966de\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Multi-center clinical trials (Phases 1\/2a and 2b) in AML were conducted with more than 100 patients treated worldwide (EU\/US\/IL)<\/p><p>In a published Phase 2b study:<\/p><ul><li><strong>36.9% complete remission<\/strong> (CR) achieved with full hematological recovery.<\/li><li>Responding patients with<strong> 79.2% overall survival<\/strong> (OS) in the first year.<strong> \u00a0<\/strong><\/li><li>Median overall survival was not reached among responders within 2 years follow-up, with <strong>66.7% OS<\/strong> in responding patient.<\/li><li>Responding patients demonstrated hematological recovery without prolonged post-remission cytopenias.<\/li><li>The treatment demonstrated a <strong>high safety profile<\/strong> as compared to cytarabine.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7879944 e-con e-atomic-element e-flexbox-base e-default-div e-7879944-b49f6f1 \" data-id=\"7879944\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"7879944\" data-e-type=\"e-flexbox\" data-id=\"7879944\">\n    \t\t<div class=\"elementor-element elementor-element-add9d33 e-transform elementor-widget elementor-widget-button\" data-id=\"add9d33\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_transform_scale_effect_hover&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:1.0500000000000000444089209850062616169452667236328125,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_hover_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_hover_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinical Research<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<div class=\"elementor-element elementor-element-95ed6ae elementor-widget elementor-widget-spacer\" data-id=\"95ed6ae\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Aspacytarabine (BST-236) Innovation Built on Established Science BioCytara&#8217;s lead development asset is Aspacytarabine (BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine. Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies. A Differentiated Cytarabine Prodrug Aspacytarabine is an investigational antimetabolite composed of cytarabine [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"class_list":["post-25","page","type-page","status-publish","hentry"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.4 - aioseo.com -->\n\t<meta name=\"description\" content=\"Aspacytarabine (BST-236) Innovation Built on Established Science BioCytara\u2019s lead development asset is Aspacytarabine (BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine.Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies. A Differentiated Cytarabine Prodrug Aspacytarabine is an investigational antimetabolite composed of cytarabine chemically\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/biocytara.com\/?page_id=25\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.4\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"BioCytara - Rethinking Cancer therapy. Advancing Leukemia Treatment.\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"PRODUCTS - BioCytara\" \/>\n\t\t<meta property=\"og:description\" content=\"Aspacytarabine (BST-236) Innovation Built on Established Science BioCytara\u2019s lead development asset is Aspacytarabine (BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine.Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies. A Differentiated Cytarabine Prodrug Aspacytarabine is an investigational antimetabolite composed of cytarabine chemically\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/biocytara.com\/?page_id=25\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-10-28T11:43:02+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-11-01T14:38:06+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"PRODUCTS - BioCytara\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Aspacytarabine (BST-236) Innovation Built on Established Science BioCytara\u2019s lead development asset is Aspacytarabine (BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine.Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies. A Differentiated Cytarabine Prodrug Aspacytarabine is an investigational antimetabolite composed of cytarabine chemically\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=25#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/biocytara.com\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=25#listItem\",\"name\":\"PRODUCTS\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=25#listItem\",\"position\":2,\"name\":\"PRODUCTS\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/#listItem\",\"name\":\"Home\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/#organization\",\"name\":\"BioCytara\",\"description\":\"Rethinking Cancer therapy. Advancing Leukemia Treatment.\",\"url\":\"https:\\\/\\\/biocytara.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/biocytara.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LogoV4.png\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=25\\\/#organizationLogo\",\"width\":883,\"height\":274},\"image\":{\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=25\\\/#organizationLogo\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=25#webpage\",\"url\":\"https:\\\/\\\/biocytara.com\\\/?page_id=25\",\"name\":\"PRODUCTS - BioCytara\",\"description\":\"Aspacytarabine (BST-236) Innovation Built on Established Science BioCytara\\u2019s lead development asset is Aspacytarabine (BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine.Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies. A Differentiated Cytarabine Prodrug Aspacytarabine is an investigational antimetabolite composed of cytarabine chemically\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/biocytara.com\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=25#breadcrumblist\"},\"datePublished\":\"2026-10-28T11:43:02+00:00\",\"dateModified\":\"2026-11-01T14:38:06+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/#website\",\"url\":\"https:\\\/\\\/biocytara.com\\\/\",\"name\":\"BioCytara\",\"description\":\"Rethinking Cancer therapy. Advancing Leukemia Treatment.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/biocytara.com\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"PRODUCTS - BioCytara","description":"Aspacytarabine (BST-236) Innovation Built on Established Science BioCytara\u2019s lead development asset is Aspacytarabine (BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine.Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies. A Differentiated Cytarabine Prodrug Aspacytarabine is an investigational antimetabolite composed of cytarabine chemically","canonical_url":"https:\/\/biocytara.com\/?page_id=25","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/biocytara.com\/?page_id=25#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/biocytara.com\/#listItem","position":1,"name":"Home","item":"https:\/\/biocytara.com\/","nextItem":{"@type":"ListItem","@id":"https:\/\/biocytara.com\/?page_id=25#listItem","name":"PRODUCTS"}},{"@type":"ListItem","@id":"https:\/\/biocytara.com\/?page_id=25#listItem","position":2,"name":"PRODUCTS","previousItem":{"@type":"ListItem","@id":"https:\/\/biocytara.com\/#listItem","name":"Home"}}]},{"@type":"Organization","@id":"https:\/\/biocytara.com\/#organization","name":"BioCytara","description":"Rethinking Cancer therapy. Advancing Leukemia Treatment.","url":"https:\/\/biocytara.com\/","logo":{"@type":"ImageObject","url":"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png","@id":"https:\/\/biocytara.com\/?page_id=25\/#organizationLogo","width":883,"height":274},"image":{"@id":"https:\/\/biocytara.com\/?page_id=25\/#organizationLogo"}},{"@type":"WebPage","@id":"https:\/\/biocytara.com\/?page_id=25#webpage","url":"https:\/\/biocytara.com\/?page_id=25","name":"PRODUCTS - BioCytara","description":"Aspacytarabine (BST-236) Innovation Built on Established Science BioCytara\u2019s lead development asset is Aspacytarabine (BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine.Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies. A Differentiated Cytarabine Prodrug Aspacytarabine is an investigational antimetabolite composed of cytarabine chemically","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/biocytara.com\/#website"},"breadcrumb":{"@id":"https:\/\/biocytara.com\/?page_id=25#breadcrumblist"},"datePublished":"2026-10-28T11:43:02+00:00","dateModified":"2026-11-01T14:38:06+00:00"},{"@type":"WebSite","@id":"https:\/\/biocytara.com\/#website","url":"https:\/\/biocytara.com\/","name":"BioCytara","description":"Rethinking Cancer therapy. Advancing Leukemia Treatment.","inLanguage":"en-US","publisher":{"@id":"https:\/\/biocytara.com\/#organization"}}]},"og:locale":"en_US","og:site_name":"BioCytara - Rethinking Cancer therapy. Advancing Leukemia Treatment.","og:type":"article","og:title":"PRODUCTS - BioCytara","og:description":"Aspacytarabine (BST-236) Innovation Built on Established Science BioCytara\u2019s lead development asset is Aspacytarabine (BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine.Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies. A Differentiated Cytarabine Prodrug Aspacytarabine is an investigational antimetabolite composed of cytarabine chemically","og:url":"https:\/\/biocytara.com\/?page_id=25","og:image":"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png","og:image:secure_url":"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png","article:published_time":"2026-10-28T11:43:02+00:00","article:modified_time":"2026-11-01T14:38:06+00:00","twitter:card":"summary_large_image","twitter:title":"PRODUCTS - BioCytara","twitter:description":"Aspacytarabine (BST-236) Innovation Built on Established Science BioCytara\u2019s lead development asset is Aspacytarabine (BST-236), an investigational anticancer therapy designed to improve the delivery characteristics of cytarabine.Our development approach is based on enhancing established therapeutic mechanisms through innovative drug design and formulation strategies. A Differentiated Cytarabine Prodrug Aspacytarabine is an investigational antimetabolite composed of cytarabine chemically","twitter:image":"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png"},"aioseo_meta_data":{"post_id":"25","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-10-28 11:43:03","updated":"2026-11-01 15:05:58"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/biocytara.com\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tPRODUCTS\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/biocytara.com\/"},{"label":"PRODUCTS","link":"https:\/\/biocytara.com\/?page_id=25"}],"_links":{"self":[{"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/pages\/25","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biocytara.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25"}],"version-history":[{"count":7,"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/pages\/25\/revisions"}],"predecessor-version":[{"id":169,"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/pages\/25\/revisions\/169"}],"wp:attachment":[{"href":"https:\/\/biocytara.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}